| Daniel Linden, | |
|
800 W Central Rd, Arlington Heights, IL 60005-2349 | |
| (877) 635-9229 | |
| (847) 618-3259 |
| Full Name | Daniel Linden |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 7 Years |
| Location | 800 W Central Rd, Arlington Heights, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720519911 | NPI | - | NPPES |
| 036152164 | Other | IL | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 036152164 (Illinois) | Secondary |
| 208M00000X | Hospitalist | 036152164 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Community Hospital 1 | Arlington heights, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Community Health Services Inc | 3375737331 | 275 |
News Archive
The risk of suffering depression increases 41% in smokers, in comparison with non-smokers. This was the conclusion of a study undertaken with 8,556 participants by scientists of the University of Navarra, in collaboration with the University of Las Palmas de Gran Canaria and the Harvard School of Public Health (USA), and which demonstrates in a pioneering way the direct relationship between tobacco use and this disease.
An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.
A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
A portable testing lab that fits into a suitcase is being hailed as the key to tackling one of the world's biggest dangers to health.
› Verified 3 days ago
| Entity Name | Northshore University Healthsystem Faculty Practice Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497701882 PECOS PAC ID: 2163334699 Enrollment ID: O20040524000118 |
News Archive
The risk of suffering depression increases 41% in smokers, in comparison with non-smokers. This was the conclusion of a study undertaken with 8,556 participants by scientists of the University of Navarra, in collaboration with the University of Las Palmas de Gran Canaria and the Harvard School of Public Health (USA), and which demonstrates in a pioneering way the direct relationship between tobacco use and this disease.
An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.
A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
A portable testing lab that fits into a suitcase is being hailed as the key to tackling one of the world's biggest dangers to health.
› Verified 3 days ago
| Entity Name | Northwest Community Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134433154 PECOS PAC ID: 3375737331 Enrollment ID: O20101103000837 |
News Archive
The risk of suffering depression increases 41% in smokers, in comparison with non-smokers. This was the conclusion of a study undertaken with 8,556 participants by scientists of the University of Navarra, in collaboration with the University of Las Palmas de Gran Canaria and the Harvard School of Public Health (USA), and which demonstrates in a pioneering way the direct relationship between tobacco use and this disease.
An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.
A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
A portable testing lab that fits into a suitcase is being hailed as the key to tackling one of the world's biggest dangers to health.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Linden, 800 W Central Rd, Arlington Heights, IL 60005-2349 Ph: (877) 635-9229 | Daniel Linden, 800 W Central Rd, Arlington Heights, IL 60005-2349 Ph: (877) 635-9229 |
News Archive
The risk of suffering depression increases 41% in smokers, in comparison with non-smokers. This was the conclusion of a study undertaken with 8,556 participants by scientists of the University of Navarra, in collaboration with the University of Las Palmas de Gran Canaria and the Harvard School of Public Health (USA), and which demonstrates in a pioneering way the direct relationship between tobacco use and this disease.
An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.
A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
A portable testing lab that fits into a suitcase is being hailed as the key to tackling one of the world's biggest dangers to health.
› Verified 3 days ago
Dr. Doron Galili, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 847-227-8987 | |
Rushabh Shah, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 877-635-9229 Fax: 847-618-3259 | |
Ahtesham Hyder, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 877-635-9229 Fax: 847-618-3259 | |
Ayham Alagha, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 877-635-9229 Fax: 847-618-3259 |